Table 2.

Treatment related adverse events

Adverse Event*	Grade 1–2	Grade 3–4	Total
	Number of patients (percent)
Hyperglycemia	16 (80)	3 (15)	19 (95)
Thrombocytopenia	12 (60)	2 (10)	14 (70)
Anemia	13 (65)	1 (5)	14 (70)
Hypertriglyceridemia	13 (65)	1 (5)	14 (70)
Cholesterol high	12 (60)	0	12 (60)
Alanine aminotransferase increased	8 (40)	2 (10)	10 (50)
Hypoalbuminemia	10 (50)	0	10 (50)
Hyponatremia	7 (35)	1 (5)	8 (40)
Aspartate aminotransferase increased	8 (40)	0	8 (40)
White blood cell decreased	4 (20)	2 (10)	6 (30)
Hypocalcemia	5 (25)	1 (5)	6 (30)
Activated partial thromboplastin time prolonged	4 (20)	2 (10)	6 (30)
Alkaline phosphatase increased	6 (30)	0	6 (30)
Creatinine increased	6 (30)	0	6 (30)
Neutropenia	2 (10)	3 (15)	5 (25)
Blood bilirubin increased	4 (20)	1 (5)	5 (25)
Diarrhea	5 (25)	0	5 (25)
Lymphopenia	1 (5)	4 (20)	5 (25)
Edema limbs	4 (20)	0	4 (20)
Mucositis	4 (20)	0	4 (20)
Cramping	4 (20)	0	4 (20)
Headache	3 (15)	0	3 (15)
Urinary tract infection	2 (10)	1(5)	3 (15)
Anorexia	2 (10)	0	2 (10)
Epistaxis	2 (10)	0	2 (10)
Hyperkalemia	2 (10)	0	2 (10)
Hypernatremia	2 (10)	0	2 (10)
Sinusitis	2 (10)	0	2 (10)
Lung infection	0	2 (10)	2 (10)
Rash	2 (10)	0	2 (10)
Colitis	0	1 (5)	1 (5)
Encephalitis	0 (0)	1 (5)	1 (5)
Febrile neutropenia	0	1 (5)	1 (5)
Sepsis	0	1 (5)	1 (5)

^*National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0